Statin-induced risk of diabetes does not reduce cardiovascular benefits in primary prevention: a 6-year propensity-score matched study in a large population
Statin therapy in primary prevention is associated with a higher risk of incident T2D, especially in hypertensive patients. However, since the final CV risk of those who develop T2D during statin treatment was lower than the one required for statin prescription according to the ESC guidelines, indicating that this phenomenon does not impair the benefit in CV prevention associated with the lipid lowering effect of statins.
Authors
- Roberto Piccinocchi (ORCID: https://orcid.org/0000-0001-9257-1123)
- Carmine Morisco (ORCID: https://orcid.org/0000-0002-2158-6317)
- Gaetano Santulli (ORCID: https://orcid.org/0000-0001-7231-375X)
- Bruno Trimarco
- Daniela Pacella (ORCID: https://orcid.org/0000-0003-2343-5069)
- Raffaele Izzo (ORCID: https://orcid.org/0000-0002-0308-2836)
- Maria Virginia Manzi (ORCID: https://orcid.org/0000-0002-1979-7131)
- Stefano Cristiano (ORCID: https://orcid.org/0009-0001-6096-2768)
- Stanislovas S. Jankauskas (ORCID: https://orcid.org/0000-0002-0843-5098)
- Giuseppe Giugliano (ORCID: https://orcid.org/0000-0002-1467-1687)
- Maria Lembo (ORCID: https://orcid.org/0000-0001-6454-2560)
- Gaetano Piccinocchi (ORCID: https://orcid.org/0000-0002-3095-2198)
- Fahimeh Varzideh (ORCID: https://orcid.org/0000-0003-2423-0831)
- Paola Gallo
- Giovanni Esposito (ORCID: https://orcid.org/0000-0003-0565-7127)
- Luca Bardi
- Valentina Trimarco (ORCID: https://orcid.org/0000-0001-5869-2247)
Institutions
- Albert Einstein College of Medicine (US)
- Feinstein Institute for Medical Research (US)
- Hodges University (US)
- Federico II University Hospital (IT)
- Società Italiana di Medicina Generale (IT)
Publication Details
- Journal
- Cardiovascular Diabetology
- Published
- 2025-05-31
- DOI
- https://doi.org/10.1186/s12933-025-02798-2
- Citations
- 6
- Primary Topic
- Lipoproteins and Cardiovascular Health
- Type
- article
- Field-Weighted Citation Impact
- 12.04
Funders
- European Commission
- National Heart, Lung, and Blood Institute